ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0241

Inequity in Disease Impact Between Male and Female Rheumatoid Arthritis Patients

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0384

Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0245

Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0017

Intra-articular Injection of Bacterial DNA Amplified from Human OA Patient Cartilage Worsens OA Outcomes in Mice

Osteoarthritis and Joint Biology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0174

Intra-rater Validation of Calcinosis Durometer Measurements in Juvenile and Adult Dermatomyositis

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0146

Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

1:00PM-3:00PM: Abstract Number: PP04

Invisible to Invincible: The Role of Virtual Events in Autoimmune Advocacy, Education and Community Building

Patient Perspectives Poster

1:00PM-3:00PM: Abstract Number: 0255

Is Abatacept as Effective and Safe in Rheumatoid Arthritis Patients with Previous Malignancy as in Those Without?

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0141

Is Rituximab Associated with Worse Outcomes in COVID-19 Patients? A Meta-analysis

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

1:00PM-3:00PM: Abstract Number: 0197

Is Similar the Same? How We Incorporated Feedback from 250 Patients into a CME Activity on Biosimilars

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0447

Is Systemic Vasculitis a Risk Factor for Myocardial Infarction? A Retrospective Cohort Study from the National Inpatient Sample

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0400

Is There Any Influence of Gender on the Sociodemographic and Clinical Characteristics of Psoriatic Arthrithis?

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0199

Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0464

JAKINIB in Refractory Giant Cell Arteritis. National Multicenter Study of 15 Cases and Literature Review

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0135

Janus Kinase Inhibitors in Severe and Refractory Inflammatory Ocular Pathology. Cases Reports and Literature Review

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].